Cell plasticity represents the ability of cells to be reprogrammed and to change their fate and
identity, enabling homeostasis restoration and tissue regeneration following damage. Cell …

The use of biomarkers in diagnosis, therapy and prognosis has gained increasing interest
over the last decades. In particular, the analysis of biomarkers in cancer patients within the …

Abstract Around 30–40% of patients with colorectal cancer (CRC) undergoing curative
resection of the primary tumour will develop metastases in the subsequent years. Therapies …

Colorectal cancer (CRC) patient-derived organoids predict responses to chemotherapy.
Here we used them to investigate relapse after treatment. Patient-derived organoids expand …

Cancer relapse after chemotherapy remains a main cause of cancer-related death. Although
the relapse is thought to result from the propagation of resident cancer stem cells, a lack of …

The cancer stem cell (CSC) concept was proposed four decades ago, and states that tumor
growth, analogous to the renewal of healthy tissues, is fueled by small numbers of dedicated …

Patient-derived organoids (PDOs) recapitulate tumor architecture, contain cancer stem cells
and have predictive value supporting personalized medicine. Here we describe a large …

Colorectal cancer stem cells (CSCs) express Lgr5 and display extensive stem cell-like
multipotency and self-renewal and are thought to seed metastatic disease. Here, we used a …

Colon cancer is the third most common cancer worldwide. Most colorectal cancer
occurrences are sporadic, not related to genetic predisposition or family history; however, 20 …

CRISPR–Cas9 technology has revolutionized genome editing and is applicable to the
organoid field. However, precise integration of exogenous DNA sequences into human …